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Glucagon, secreted from pancreatic islet a cells, stimulates gluconeogenesis and liver glycogen breakdown. The
mechanism regulating glucagon release is debated, and variously attributed to neuronal control, paracrine control by
neighbouring b cells, or to an intrinsic glucose sensing by the a cells themselves. We examined hormone secretion and
Ca
2þ responses of a and b cells within intact rodent and human islets. Glucose-dependent suppression of glucagon
release persisted when paracrine GABA or Zn
2þ signalling was blocked, but was reversed by low concentrations (1–20
lM) of the ATP-sensitive K
þ(KATP) channel opener diazoxide, which had no effect on insulin release or b cell responses.
This effect was prevented by the KATP channel blocker tolbutamide (100 lM). Higher diazoxide concentrations ( 30
lM) decreased glucagon and insulin secretion, and a- and b-cell Ca
2þ responses, in parallel. In the absence of glucose,
tolbutamide at low concentrations (,1 lM) stimulated glucagon secretion, whereas high concentrations (.10 lM)
were inhibitory. In the presence of a maximally inhibitory concentration of tolbutamide (0.5 mM), glucose had no
additional suppressive effect. Downstream of the KATP channel, inhibition of voltage-gated Na
þ (TTX) and N-type Ca
2þ
channels (x-conotoxin), but not L-type Ca
2þ channels (nifedipine), prevented glucagon secretion. Both the N-type Ca
2þ
channels and a-cell exocytosis were inactivated at depolarised membrane potentials. Rodent and human glucagon
secretion is regulated by an a-cell KATP channel-dependent mechanism. We propose that elevated glucose reduces
electrical activity and exocytosis via depolarisation-induced inactivation of ion channels involved in action potential
firing and secretion.
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Introduction
Blood glucose levels are under the control of two hormones
released from the pancreatic islets of Langerhans. Islet b cells
secrete insulin when glucose is high, decreasing glucose
production by the liver and increasing glucose storage in
multiple tissues. Regulated insulin secretion is relatively well
understood, involving the metabolic stimulation of electrical
activity, Ca
2þ entry, and exocytosis [1]. Islet a cells secrete
glucagon in response to decreased blood glucose, whereas
elevated glucose levels suppress glucagon release. Glucagon is
the principal factor stimulating glucose production by the
liver. In diabetes, baseline glucagon release is elevated, and
glucagon secretion in the low-glucose condition is blunted [2–
4]. These effects contribute to chronic hyperglycaemia and to
an increased risk for acute hypoglycaemic events.
The mechanism regulating glucagon secretion is poorly
understood and remains hotly debated [5]. Glucagon release
in rodents may be regulated by paracrine signals, including c-
aminobutyric acid (GABA) [6,7], Zn
2þ [8], and insulin [9,10].
Conversely, glucose may suppress glucagon secretion through
a direct effect on a-cell activity [11–14]. There are also studies
suggesting that glucagon secretion is under hypothalamic
control [15,16]. Human in vivo studies provide conﬂicting
evidence regarding the control of glucagon secretion by
paracrine or intrinsic regulation of a cells [17–30], and very
little work has been done to examine this question in isolated
human islets.
Islet a cells express ATP-dependent K
þ (KATP) channels
[9,13,14,31,32] that can be closed by ATP [9,31]. Glucose
increases intracellular free ATP in a cells [8,10], although
reports vary as to the ability of glucose to inhibit a-cell KATP
channels [13,31,33]. Evidence from SUR1
 /  mice implicate
KATP channels as regulators of glucagon release [13,34,35].
However, because both a and b cells possess molecularly
identical KATP channels [36,37], it is not clear how KATP-
mediated depolarisation would stimulate insulin secretion
but suppress glucagon secretion.
The answer may lie in the downstream machinery regulat-
ing electrical activity and Ca
2þ entry. Unlike b cells, a cells
possess a large voltage-dependent Na
þ c u r r e n tt h a ti s
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PLoS BIOLOGYessential for glucagon release [14,33]. We have previously
proposed that the depolarisation-induced inactivation of this
channel contributes to the cessation of action potential ﬁring
[14]. Additionally, activation of voltage-dependent Ca
2þ
channels (VDCCs) is essential for Ca
2þ entry and a-cell
function [38,39]. Accordingly, the a-cell intracellular Ca
2þ
([Ca
2þ]i) oscillations (reﬂecting a-cell electrical activity) are
suppressed in parallel with glucagon release by glucose [40].
Multiple VDCCs regulate glucagon release [14,41–43],
although the N-type channels appear to be particularly
important for glucagon release evoked by hypoglycaemia
alone [33,44,45], at least in mouse islets. This is in contrast to
the b cell in which the L-type VDCC functionally predom-
inates [46].
We have now compared insulin and glucagon release and a-
and b-cell Ca
2þ responses in intact mouse, rat, and human
pancreatic islets. We show that glucose retained the ability to
suppress glucagon release from isolated islets during block-
ade of the Zn
2þ and GABA paracrine pathways, and in the
absence of stimulated insulin secretion or b-cell Ca
2þ
responses. Thus we now provide evidence in both rodent
and human islets supporting the direct (intrinsic) glucose
regulation of glucagon release from pancreatic a cells.
Results
Glucose Can Regulate Glucagon Secretion Directly
To examine a role for GABA and Zn
2þ as paracrine
mediators of glucagon secretion, we examined the ability of
the GABAA receptor antagonist SR-95531 and Zn
2þ chelation
with Ca
2þ-EDTA to prevent the glucose-dependent suppres-
sion of glucagon release. Glucose, at concentrations (7 and 8.3
mM) just above the threshold for insulin release (see below),
suppressed glucagon secretion from isolated mouse (Figure
1A) and rat islets (Figure 1B) by 60% (n ¼ 15, p , 0.001) and
57% (n ¼ 10, p , 0.001), respectively. In both mouse and rat
islets, the ability of glucose to inhibit glucagon secretion
persisted in the presence of Ca
2þ-EDTA (43% and 48%, n ¼
10, p , 0.001, respectively) and SR-95531 (31% and 46%, n¼8
and 10, p , 0.01 and p , 0.001, respectively) (Figure 1).
It is worth noting that in the presence of the GABAA
antagonist, glucagon secretion was increased under both low-
and high-glucose conditions, and furthermore, glucose was
approximately 50% less effective in suppressing glucagon
release from mouse islets (31% versus 60%, respectively)
(Figure 1A). Additionally, somatostatin released from pan-
creatic d cells is suggested to be a potential paracrine
regulator of glucagon secretion. However, the somatostatin
receptor 2 (SSTR-2) antagonist PRL-2903 does not interfere
with the ability of glucose (at 3 and 7 mM) to inhibit glucagon
secretion from mouse islets [47]. Like the GABAA receptor
Figure 1. Glucose Suppresses Glucagon Release Independently of
Paracrine Signals Mediated by Zn
2þ or GABA.
(A) Glucagon release from isolated mouse islets was suppressed by 60%
at 7 mM glucose compared with 1 mM (filled bars). Glucose retained its
suppressive effect on glucagon release under conditions of Zn
2þ
chelation (Ca
2þ-EDTA) (open bars) and antagonism of GABAA receptors
(SR-95531) (shaded bars). Antagonism of GABAA receptors increased
both basal and glucose-suppressed glucagon secretion, suggesting a
paracrine role for GABA independent of the glucose effect.
(B) As in (A), but using rat islets.
*, p , 0.05; **, p , 0.01; ***, p , 0.001, compared with 1 mM glucose, or
as indicated.
doi:10.1371/journal.pbio.0050143.g001
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Author Summary
Glucagon is a critical regulator of glucose homeostasis. Its major
action is to mobilize glucose from the liver. Glucagon secretion from
a cells of the pancreatic islets of Langerhans is suppressed by
elevated blood sugar, a response that is often perturbed in diabetes.
Much work has focused on the regulation of a-cell glucagon
secretion by neuronal factors and by paracrine factors from
neighbouring cells, including the important islet hormone insulin.
In contrast, we provide evidence in support of a direct effect of
glucose on a cells within intact rodent and human islets. Notably,
our work implicates an a-cell glucose-sensing pathway similar to
that found in insulin-secreting b cells, involving closure of ATP-
dependent K
þchannels in the presence of glucose. Furthermore, we
find that membrane depolarisation results in inhibition of Na
þ and
Ca
2þ channel activity and a-cell exocytosis. Thus, we propose that
elevated blood glucose reduces a-cell electrical activity and
glucagon secretion by inactivating the ion channels involved in
action potential firing and secretion.antagonist, however, PRL-2903 increased glucagon secretion
in low-glucose conditions [47]. Thus, although the present
data do not entirely rule out these pathways as modulators of
glucagon secretion, glucose is clearly able to suppress
glucagon secretion independently of these.
a-Cell KATP Channels Regulate Glucagon Secretion
We next examined glucagon and insulin secretion during
pharmacological manipulation of KATP channel activity. Here
we have examined the role of KATP channels in intact islets by
applying an indirect, but minimally invasive, technique. It
would have been difﬁcult (if not impossible) to study the
effects of glucose on a-cell KATP channel activity using the
patch-clamp technique because of the smallness of the a-cell
resting conductance (0.15 nS/pF in the absence of glucose, of
which two thirds is attributable to KATP channels) [13]. We
have instead used increasing concentrations of diazoxide and
tolbutamide to ‘‘titrate’’ the inﬂuence of KATP channel
activity on a-cell [Ca
2þ]i and glucagon secretion. Increasing
concentrations of the KATP channel activator diazoxide
demonstrated that moderate activation of KATP channels
(0.3–10 lM diazoxide) relieved the suppression of glucagon
secretion from both mouse (Figure 2A) and rat (Figure 2B)
islets. Stimulation of glucagon release was half-maximal at
approximately 1 lM diazoxide, which is well below that
required to inhibit insulin release, suggesting that ‘‘re-
activation’’ of glucagon release was not secondary to reduced
b-cell secretion. Increasing the concentration of diazoxide
beyond 10 lM inhibited glucagon secretion in parallel with
an inhibition of insulin release from both mouse and rat islets
(Figure 2A and 2B). When instead applied in the presence of 1
mM glucose (at which concentration glucagon secretion is
stimulated), increasing diazoxide produced a monotonic
inhibition of glucagon secretion (Figure 2C) with a half-
maximal inhibitory concentration (IC50) that is much lower
than what is seen under high-glucose conditions (;2 lM
versus ;50 lM).
In the complete absence of glucose, when KATP channels
are expected to be open, the KATP channel antagonist
tolbutamide also produced a biphasic effect on glucagon
release. Augmentation of glucagon secretion was seen at
tolbutamide concentrations of up to 1 lM (stimulation being
half-maximal at 0.1 lM), whereas inhibition was observed at
higher concentrations (Figure 2D). Importantly, in the
presence of a maximally inhibitory tolbutamide concentra-
tion (0.5 mM), glucose was unable to produce any further
inhibition of glucagon release (Figure 3A). These data are
inconsistent with the idea that b-cell secretion is the primary
inhibitor of a-cell glucagon release. They also suggest that
glucagon secretion is maximal within a ‘‘window’’ of
intermediate KATP channel activity.
To further investigate the role of a-cell KATP channels as
regulators of glucagon secretion, we studied islets from
Kir6.2Y12X mice, which posses a Tyr12STOP mutation in
the Kcnj11 gene, leading to premature termination of the
KATP channel pore-forming subunit [48]. At low-glucose
concentrations, glucagon secretion from the Kir6.2Y12X
islets was already suppressed compared with that from wild-
type islets (Figure 3B), similar to the effect of glucose
stimulation or pharmacological KATP channel inhibition
observed in Figures 2D and 3A. Consistent with a recent
report [49], higher glucose levels stimulated glucagon
secretion, perhaps due to a direct effect of metabolism on
secretion [33]. In wild-type islets, glucagon secretion ex-
hibited a nadir at 5 mM glucose, and glucagon secretion at 20
mM glucose was 40% higher than at 5 mM glucose. Insulin
secretion in the Kir6.2Y12X islets was elevated at low-glucose
Figure 2. Glucagon Release from Isolated and Intact Mouse Islets Is Regulated by a KATP Channel-Dependent Pathway
(A) Glucagon (filled circles) and insulin (open circles) secretion measured from mouse islets in the presence of 8.3 mM glucose at increasing
concentrations of diazoxide.
(B) As in (A), but using rat islets. The glucagon responses to 1 mM glucose (filled square) and 100 lM tolbutamide (filled triangle) are indicated.
(C) As in (A), but in the presence of 1 mM glucose and only measuring glucagon secretion.
(D) As in (A), but examining the effect of tolbutamide in the absence of glucose. Glucagon secretion in response to 20 mM glucose is indicated by the
filled square.
*, p , 0.05; **, p , 0.01; ***, p , 0.001, compared with zero diazoxide (A–C) or zero tolbutamide (D).
doi:10.1371/journal.pbio.0050143.g002
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KATP Regulation of Glucagon Releaseconcentrations (Figure 3C), whereas glucose-stimulated in-
sulin secretion was blunted. It is notable that the increase in
glucagon release from the Kir6.2Y12X islets was coincident
with increased insulin secretion, reinforcing the view that
inhibition of glucagon is not mediated by a factor released by
the b cells. Furthermore, in control islets, the inhibition of
glucagon secretion is maximal at a concentration of glucose
(5 mM) that is without stimulatory action on insulin secretion.
We next examined the function of a and b cells in situ by
monitoring the [Ca
2þ]i responses of single cells within intact
mouse islets. These were functionally identiﬁed by their
[Ca
2þ]i response to 0.5, 2, and 11 mM glucose [50]. Glucose
stimulation suppressed the [Ca
2þ]i response of a cells by 51 6
3% (n¼63 cells in 15 islets, p , 0.001) (Figure 4A and 4B). The
suppressive effect of glucose was alleviated (to 101 6 11% of
initial values) by application of 2 lM diazoxide (Figure 4A
and 4B). This concentration of diazoxide was similar to that
which produced maximal stimulation of glucagon secretion
and much (;15-fold) lower than necessary to inhibit insulin
secretion (Figure 2B) or b-cell [Ca
2þ]i responses to glucose
(Figure 4A).
KATP Channels Regulate Human a-Cell Activity
Little work has been done to examine the mechanism of
glucose-regulated glucagon secretion from isolated human
islets [51]. Glucagon and insulin secretion from islets isolated
from healthy donors was examined. Similar to above,
glucagon secretion from human islets was suppressed by 58
6 3% (n¼9, p , 0.05) upon raising the glucose concentration
from 0 to 10 mM. Tolbutamide (200 lM) inhibited glucagon
release by 43 6 14% (n ¼ 7, p , 0.05). At the same time,
insulin secretion was increased 6.4- and 4.4-fold by glucose
and tolbutamide stimulation, respectively (Figure 5A). Mod-
erate re-activation of KATP channels with 2 lM diazoxide
antagonized the glucose-induced suppression of glucagon
release (n ¼ 7, p , 0.01) (Figure 5B). A 10-fold higher
concentration of diazoxide had signiﬁcantly less stimulatory
effect (p , 0.001 versus 2 lM diazoxide), and in the presence
of 200 lM diazoxide, glucagon secretion was not different
from that observed in the absence of the KATP channel
activator. Importantly, the lowest concentration of diazoxide
(2 lM), which produced the strongest stimulation of glucagon
secretion, had no inhibitory effect on glucose-stimulated
insulin secretion (n ¼ 5), whereas 20 and 200 lM produced
partial or complete inhibition of insulin secretion. The
GABAA receptor antagonist SR95531 had no effect on
glucose-induced inhibitiono fg l u c a g o ns e c r e t i o nf r o m
human islets, and whole-cell voltage-clamp measurements
indicate that human a cells, unlike human b and d cells,
express few if any GABAA receptor Cl
 channels (M. Braun, R.
Ramracheya, and P. Rorsman, unpublished data).
Examination of the Ca
2þ responses of single a and b cells
within intact human islets demonstrated that glucose
decreased [Ca
2þ]i by 62 6 3% (n ¼ 42 cells in 7 islets, p ,
0.001) in a cells, and that this effect could be completely
reversed by 2 lM diazoxide (Figure 6A and 6B). Furthermore,
the re-activation of a-cell [Ca
2þ]i responses by diazoxide could
be prevented by application of 100 lMt o l b u t a m i d e ,
conﬁrming the role of KATP channels (Figure 6C). An analysis
of the dose–response relationship to diazoxide demonstrated
a maximally effective concentration of 1.7 lM (Figure 6D and
6E; n ¼ 38 cells in 9 islets), far below the concentration
necessary to block b-cell responses (Figure 6D). Increases in
diazoxide above 20 lM blocked the [Ca
2þ]i responses of a cells
and b cells in parallel, consistent with the effect on glucagon
and insulin release.
Na
þ Channels Regulate Low-Glucose–Stimulated
Glucagon Secretion
The above data suggest that glucose-dependent inhibition
of a-cell KATP channels is involved in the suppression of
glucagon secretion. It is not clear however, how KATP channel
Figure 3. Tolbutamide and Glucose Effects Are Non-Additive and
Glucagon Response Is Altered in Kir6.2Y12X Islets That Express a
Truncated Kir6.2 Subunit
(A) Glucagon release from isolated mouse islets at 1 (open bars) and 20
mM glucose (filled bars) under control conditions and presence of 0.5
mM tolbutamide.
(B) A glucose dose-response of glucagon release from control C3HB islets
(filled circles) and Kir6.2Y12X islets (open circles).
(C) As in (B), but insulin was measured.
*, p , 0.05; **, p , 0.01; ***, p , 0.001, compared with control.
doi:10.1371/journal.pbio.0050143.g003
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KATP Regulation of Glucagon Releaseinhibition and membrane depolarisation result in suppres-
sion of secretion. Unlike in b cells, a-cell Na
þ channels are
active in the physiological range of membrane potentials.
Previous work from our group suggested that the voltage-
dependent inactivation of Na
þ channels, which in mouse a
cells is half-maximal at  42 mV [43], contributes to cessation
of electrical activity upon a-cell depolarisation [14]. We thus
used the voltage-dependent Na
þ channel antagonist tetrodo-
toxin (TTX) to test a role for these channels in a-cell function
and glucagon secretion. TTX (0.1 lg/ml) suppressed glucagon
release from mouse islets by 56 6 5% (n ¼ 10, p , 0.001)
under low-glucose conditions (Figure 7A). This effect of TTX
in the low-glucose condition was similar to what we observed
with high-glucose stimulation alone. With TTX present,
glucose was without further inhibitory action, suggesting that
glucose inhibits glucagon secretion through a Na
þ channel-
dependent mechanism. TTX has no effect on glucose-
stimulated insulin secretion in mouse islets (Figure 7A); again
suggestive of a direct rather than indirect effect on a cells. In
accordance with this, application of 0.1 lg/ml TTX to mouse
islets reversibly abolished the a-cell [Ca
2þ]i response evoked
by low-glucose concentrations (Figure 7B and 7C; n¼18 cells
in 4 islets), but had no effect on b-cell [Ca
2þ]i (unpublished
data).
N-Type Ca
2þ Channels Mediate the Ca
2þ Influx That
Triggers Glucagon Secretion and a-Cell Exocytosis
Downstream of Na
þ channel activation, the opening of
VDCCs allows Ca
2þ into a cells, triggering the exocytosis of
glucagon-containing vesicles. We applied whole-cell patch-
clamp recordings to establish the a-cell Ca
2þ channel
complement. The integrated whole-cell Ca
2þ current meas-
ured during 50-ms depolarisations from  70 mV to 0 mV
amounted to 6.2 6 0.8 pC (n ¼ 15) under control conditions,
2.6 6 0.8 pC (n ¼ 10; p , 0.05) in the presence of 50 lM
nifedipine, and 4.1 6 0.5 pC (n¼12; p , 0.01) in the presence
of 1 lM x-conotoxin. Thus, L- and N-type Ca
2þ channels
account for 58% and 34% of the a-cell Ca
2þ current,
respectively.
Figure 8A compares glucagon secretion at 1 and 20 mM
glucose under control conditions and in the presence of 100
nM x-conotoxin and 20 lM nifedipine, respectively. We
found that whereas the L-type channel blocker nifedipine
had no effect on glucagon release at 1 or 20 mM glucose, the
N-type Ca
2þ channel blocker x-conotoxin inhibited the
release of the hormone to a level similar to that of high
glucose, tolbutamide, and TTX. Furthermore, glucose exerted
no additional inhibitory action in the presence of x-
conotoxin. Thus, glucagon secretion stimulated by low-
glucose levels depends principally on Ca
2þ inﬂux through
N-type channels, although these only account for one third of
the Ca
2þ current. We conﬁrmed this Ca
2þ channel depend-
ence by conducting high-resolution single-cell capacitance
measurements of exocytosis (Figure 8B). Exocytosis elicited
by 500-ms step depolarisations from  70 to 0 mV averaged
approximately 150 fF (corresponding to the fusion of ;75
Figure 4. The Intracellular Ca
2þ Response of Single a Cells within Intact Islets Can Be Re-Activated by Low Concentrations of Diazoxide
(A) Representative intracellular Ca
2þ responses from a and b cells within an intact mouse islet exposed to 0.5 mM glucose, 11 mM glucose, and 11 mM
glucose plus 2 lM diazoxide (diaz) as indicated above the traces.
(B) The Ca
2þ response of a cells was suppressed by 11 mM glucose, and could be reactivated with low concentrations of the KATP channel agonist
diazoxide. ***, p , 0.001, compared with the low-glucose condition, or as indicated.
doi:10.1371/journal.pbio.0050143.g004
Figure 5. Glucagon Release from Isolated and Intact Human Islets Is
Regulated by a KATP Channel-Dependent Pathway
(A) Glucagon (open bars) and insulin (filled bars) release was measured
from isolated human islets under control conditions and following
addition of 10 mM glucose or 200 lM tolbutamide.
(B) Glucagon (open bars) and insulin secretion (filled bars) measured in
the presence of 10 mM glucose and increasing concentrations of
diazoxide (0–200 lM).
*, p , 0.05; **, p , 0.01; ***, p , 0.001, compared with controls, unless
otherwise indicated.
doi:10.1371/journal.pbio.0050143.g005
PLoS Biology | www.plosbiology.org June 2007 | Volume 5 | Issue 6 | e143 1240
KATP Regulation of Glucagon Releasesecretory granules with the plasma membrane [43]) under
control conditions (Ctrl). This response was not signiﬁcantly
affected by 50 lM nifedipine (nif), but was nearly abolished by
1 lM x-conotoxin (x-con; Figure 8C).
Inactivation of N-Type Ca
2þ Channels Underlie Glucose
Inhibition of Glucagon Secretion
We next examined the mechanism by which N-type
channels regulate glucagon release in response to membrane
depolarisation/hyperpolarisation in mouse a cells. Non–L-
type (isradipine-resistant) Ca
2þ currents were elicited by step
depolarization to 0 mV in the absence (black) or presence
(red) of 1 lM x-conotoxin following a 200-ms conditioning
pulse to  70 mV (Figure 9A) or þ10 mV (Figure 9B). It is
evident that the x-conotoxin–sensitive component was
abolished by the þ10 mV conditioning pulse. Figure 9C
summarizes the relationship between the conditioning
voltage and the Ca
2þ current amplitude in the absence (open
squares) and presence (circles) of x-conotoxin (upper panel).
The x-conotoxin–sensitive N-type Ca
2þcurrent component is
shown in the lower panel of Figure 9C, and underwent
voltage-dependent inactivation that was half-maximal (V0.5)
at  31 6 6m V( n ¼ 6). A residual, x-conotoxin–insensitive
Ca
2þ current also appears to undergo voltage-dependent
inactivation (Figure 9C). This accounts for less than 15% of
the inactivating current, and may be attributable to T-type
Ca
2þ channels that have been reported in a cells [14].
In Figure 9D, we examined the voltage-dependent activation
of a-cell exocytosis using step-wise depolarisations (500 ms)
from  70 mV to between  50 and 20 mV (Figure 9D). The
capacitance response versus voltage relationship (Figure 9E)
demonstrates a marked increase in the capacitance response
between  10 and 10 mV. Thus any reduction in action
potential amplitude within this range would severely attenu-
ate a-cell exocytosis.
The voltage-dependent inactivation of a-cell exocytosis was
examined next (Figure 9F). Cells were held at conditioning
potentials between  70 and  30 mV, after which exocytosis
was elicited by depolarisation to 0 mV. Exocytosis stimulated
from the 30 mV conditioning potential was only 25% of that
elicited from  70 mV (Figure 9G). This voltage-dependent
Figure 6. Intracellular Ca
2þ Responses of a Cells within Intact Human Islets Are Regulated by a KATP Channel-Dependent Mechanism
(A) Ca
2þ responses measured in two human a cells within the same islet at 0.5 mM and 11 mM glucose (glu), in the presence of 2 lM diazoxide (diaz).
(B) Summary of the Ca
2þ responses at 0.5 mM glucose, at 11 mM glucose, in the presence of glucose (11 mM) and diazoxide (2 lM), and following the
removal of diazoxide, but in the continued presence of 11 mM glucose.
(C) The re-activation of human a-cell Ca
2þresponses by 2 lM diazoxide was reversed upon application of the KATP channel antagonist tolbutamide (100
lM).
(D) The effects of increasing concentrations of diazoxide on the Ca
2þ response of a human a cell and b cell within the same islet exposed to 11 mM
glucose. At the end of the experiment, diazoxide was withdrawn and glucose lowered to 0.5 mM.
(E) Dose-response curve for the effect of diazoxide on a-cell Ca
2þ responses. The grey horizontal line indicates the response with 11 mM glucose alone.
*, p , 0.05; **, p , 0.01; ***, p , 0.001, compared with controls, unless otherwise indicated.
doi:10.1371/journal.pbio.0050143.g006
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inactivation of the N-type Ca
2þ channels. The fact that
inhibition of exocytosis appears to occur at more-negative
voltages than that documented for the inactivation of the N-
type Ca
2þ channels can be attributed to the brevity of the
conditioning pulses in Figure 9A–9C (200 ms), whereas in
Figure 9G the holding potential was varied.
Discussion
Regulated glucagon secretion from pancreatic a cells is a
major component of the counter-regulatory response to
hypoglycaemia. Diabetes mellitus is associated with defects of
glucagon secretion that exacerbate the consequences of
impaired insulin secretion [2–4]. The mechanism regulating
the release of this important hormone is incompletely
understood and currently the source of much debate. In the
present study we examined glucagon secretion and the [Ca
2þ]i
response of in situ a cells of isolated rodent and human islets.
We further characterised the Ca
2þ currents and capacitance
changes of single isolated a cells, to dissect the mechanism
regulating downstream control of glucagon release.
Previous work with genetic mouse models, including
SUR1
 /  [13,34,35] and Kir6.2
 /  [16] mice, suggests an
important role for KATP channels in glucagon secretion.
Three pieces of evidence argue for the importance of islet
KATP channels in glucagon secretion. First, introduction of
the Tyr12STOP mutation into the KATP channel subunits in
the Kir6.2Y12X islets results in suppression of glucagon
secretion at low-glucose levels and causes loss of glucose-
induced inhibition of secretion. Second, the KATP channel
inhibitor tolbutamide when applied at maximally effective
concentrations inhibits glucagon secretion from isolated
islets. Third, a low dose of the KATP channel activator
diazoxide restores a-cell Ca
2þ responses and glucagon
secretion in high-glucose conditions. What is not immediately
clear from these arguments, and from the previous SUR1
 / 
genetic studies, is whether glucagon is being controlled by the
a-cell or the b-cell KATP channels, as the latter may regulate a-
cell function indirectly via paracrine pathways. We therefore
examined insulin and glucagon secretion, and the Ca
2þ
responses of a and b cells in situ in parallel to determine
the functional relationship between these cells. Furthermore,
we measured the glucagon response to glucose during
blockade of putative paracrine signalling pathways.
Studies on rat islets support an important role for
paracrine signals as regulators of glucagon release
Figure 7. Glucagon Secretion and a-Cell Ca
2þ Responses Are Dependent
upon the Activity of Voltage-Dependent Na
þ Channels
(A) Glucagon (open bars) and insulin (filled bars) release from isolated
mouse islets at 1 mM and 20 mM glucose, under control conditions and
in the presence of the Na
þ channel antagonist TTX (0.1 lg/ml).
(B) Intracellular Ca
2þ response of single a cells to 0.5 mM glucose. TTX
(0.1 lg/ml) was included in the perfusion medium during the indicated
period.
(C) The effects of TTX and glucose on a-cell Ca
2þ responses. Note that
TTX inhibits Ca
2þ responses as effectively as glucose and that the action
is at least partially reversible.
*, p , 0.05; **, p , 0.01; ***, p , 0.001, compared with controls, unless
otherwise indicated.
doi:10.1371/journal.pbio.0050143.g007
Figure 8. Glucagon Secretion Is Regulated by N-Type Ca
2þ Channels
(A) Glucagon release measured at 1 (open bars) and 20 mM glucose (filled bars) under control conditions and in the presence of 100 nM x-conotoxin
(middle) or 20 lM nifedipine (right).
(B) Exocytosis was elicited by 500-ms depolarisations from 70 to 0 mV under control conditions (Ctrl) and in the presence of either nifedipine (50 lM;
nif) or x-conotoxin (1 lM; x-con).
(C) Summary of the exocytotic response under control conditions and in the presence of nifedipine and x-conotoxin.
*, p , 0.05; **, p , 0.01, compared with 1 mM glucose and the control capacitance response, unless indicated otherwise.
doi:10.1371/journal.pbio.0050143.g008
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KATP Regulation of Glucagon Release[33,52,53], whereas the case for paracrine regulation of
glucagon secretion from mouse and human a cells is less
clear [9,10,14,17–21,27]. Although it is clear that Zn
2þ, GABA,
and somatostatin can exert a paracrine control of glucagon
secretion under certain conditions, the data shown here
ﬁrmly establish that glucose can suppress glucagon secretion
independently of these pathways as demonstrated in Figure 1
(and in [47]). Furthermore, and in agreement with recently
published results [47], maximal inhibition of glucagon release
occurs at levels equal to or lower than 5 mM glucose, whereas
the stimulation of insulin release requires glucose levels
greater than 5 mM (Figure 3), suggesting that products of b-
cell secretion are not required for suppression of glucagon
release.
This conclusion is further underpinned by the signiﬁcant
discordance between insulin and glucagon release, and the b-
and a-cell Ca
2þ responses, under several conditions: (1) low
doses of the KATP channel opener diazoxide that stimulate
glucagon secretion while not affecting insulin release; (2) high
doses of diazoxide at which suppression of b-cell secretion
would be expected to elevate glucagon release; (3) in the
Kir6.2Y12X islets; and (4) in response to the Na
þ channel
blocker TTX. Therefore, our data argue that glucagon-
producing a cells possess an intrinsic mechanism for
regulation by glucose and that involves KATP channels. This
is at variance with the data of Liu et al. [12] who report that
tolbutamide has no effect on [Ca
2þ]i in single, isolated a cells,
but in agreement with the conclusion of Ostenson et al. [54],
that sulfonylureas can inhibit glucagon secretion by a direct,
non-paracrine mechanism.
On the basis of our ﬁndings, we propose that a-cell
glucagon secretion occurs within a narrow window of
intermediate KATP channel activity (and thus membrane
potential) (Figure 10). That is, if the a cell is either too
hyperpolarised (maximal KATP activity) or too depolarised
(maximal KATP inhibition), then glucagon secretion is sup-
pressed. This is supported by the biphasic effects of both
diazoxide and tolbutamide. Whereas the former (in high
glucose) brings the a cell in a dose-dependent manner
through the membrane potential window supporting gluca-
gon secretion in the depolarised (low KATP) to hyperpolarised
(high KATP) direction (Figure 10C), the latter (in zero glucose)
brings the a cell through the window in the opposite
direction (from hyperpolarised to depolarised) (Figure 10B).
Thus, glucose likely leads to the suppression of glucagon
secretion by depolarising the a-cell membrane potential
above the range that supports glucagon secretion (Figure
10A). Indeed, in some (but not all, see [55]) studies, glucose
was found to depolarize mouse and rat a cells and reduce
action potential amplitudes [13,52]. It is interesting that
whereas low concentrations of glucose were without stim-
ulatory effect, tolbutamide (0.1–1 lM) stimulated glucagon
release beyond that observed at zero glucose. Thus, small
depolarisations (as previously documented for arginine [13])
exert a positive ‘‘chronotropic’’ effect in a cells and thus
stimulate glucagon release. The fact that glucose did not
share this ability indicates that the depolarisation produced
by 1 mM glucose results in sufﬁcient inactivation of the
currents to balance any increase in action potential fre-
quency.
Previous human studies have employed pharmacological
KATP channel antagonists [23,24] or agonists [25,26] to
examine the regulation of glucagon release in vivo. These
were interpreted with the assumption that pharmacological
KATP modulation only affects the b cells, and that any change
in glucagon release was therefore secondary to altered b-cell
function. Our data establish that KATP channel modulation
has dramatic and direct effects on glucagon secretion and
Ca
2þ signalling in human a cells under conditions in which
insulin secretion is unaffected. Thus, the in vivo manipulation
of a-cell KATP channel activity in the above studies may well
have involved direct effects on a-cell function that con-
tributed to the observed changes in glucagon release.
Figure 9. Voltage-Dependent Inactivation of a-Cell N-Type Ca
2þCurrents
and Exocytosis
(A) N-type Ca
2þ currents were evaluated during blockade of the L-type
channels with isradipine (2 lM). The N-type channel antagonist x-
conotoxin (1 lM; red traces) reduced the Ca
2þ current elicited by a step
depolarisation from  70 to 0 mV (right).
(B) As in (A), but the pulse to 0 mV was preceded by a 200-ms
conditioning depolarization to þ10 mV. x-Conotoxin was without effect
on the current measured during the depolarization to 0 mV under these
conditions (right).
(C) Top: peak Ca
2þ currents measured in the presence of 2 lM isradipine
alone (open squares) or together with 1 lM x-conotoxin (red circles)
during a depolarization to 0 mV following 200-ms conditioning pulses to
between  70 and þ70 mV. Lower: inactivation of the x-conotoxin–
sensitive component. Half-maximal inactivation of the N-type current
was at  31 6 6m V( n ¼ 5).
(D) Exocytosis was elicited with 500-ms depolarisations from  70 mV to
between  50 and 20 mV.
(E) The voltage dependence of the exocytotic response.
(F) Exocytosis elicited by 500-ms depolarisations to 0 mV from holding
potentials of between  70 and  30 mV.
(G) Summary of effects of holding potential on exocytotic responses
elicited by depolarisations to 0 mV. Data have been normalized to
responses obtained using a holding potential of  70 mV.
*, p , 0.05; **, p , 0.01; ***, p , 0.001, compared with x-conotoxin (C,
top) or with the initial response.
doi:10.1371/journal.pbio.0050143.g009
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glucagon release is nicely highlighted by a study investigating
the effects of the common Glu23Lys (E23K) polymorphism of
the Kir6.2 subunit of the KATP channel on insulin and
glucagon secretion in non-diabetic human patients [29]. This
variant of the channel leads to a slight decrease in the ATP
sensitivity of the channel. The functional signiﬁcance of this
was examined by comparing hormone release during hyper-
glycaemic clamps in individuals carrying the polymorphism
or not. Although insulin secretion in homozygous Glu23Lys
individuals was not different from controls, glucose-induced
suppression of glucagon release was blunted [29]. This
becomes understandable in light of the effect of diazoxide
on isolated human islets (Figures 4 and 5). Half-maximal
activation of KATP channels occurs at diazoxide concentra-
tions of 20–100 lM (depending on the intracellular ATP level)
[56]. If the Glu23Lys polymorphism increases KATP channel
activity to the same extent as 0.3–1.5 lM diazoxide, the
concentration at which an effect on glucagon release is ﬁrst
seen, then the effect will be very difﬁcult to detect with
electrophysiology, perhaps explaining why some studies have
failed to detect a functional effect of the polymorphism
(reviewed in [57]). Nevertheless, such small changes can have
signiﬁcant biological effects, as illustrated by the glucagon
release data, and may contribute to pathological states such as
impaired glucose tolerance and diabetes. Thus, the reduced
ability of glucose to inhibit glucagon secretion in individuals
carrying the Glu23Lys variant of the KATP channel likely
results from the failure of these channels to undergo
complete inhibition in response to glucose.
We have proposed that glucagon secretion is stimulated
within a window of intermediate a-cell KATP channel activity,
and that glucagon release is suppressed by either increases or
decreases in KATP channel activity. How is this accomplished?
Brieﬂy, we suggest that this window is the result of (1) the
ability of intermediate KATP channel activity to support
regenerative electrical responses through the activation of
voltage-dependent Na
þ and N-type Ca
2þ channels (grey in
Figure 10); (2) the failure of the Na
þ and Ca
2þ channels to
activate when a cells are hyperpolarised by the opening of a
major fraction of KATP channels (above the grey in Figure 10);
and (3) the voltage-dependent inactivation of the Na
þ [14] and
N-type Ca
2þ channels when KATP channels are closed and the
a-cell membrane potential is depolarised (below the grey in
Figure 10). Thus, the differential responsiveness of a and b
cells to diazoxide does not result from differential sensitiv-
ities of the KATP channels in these cells, but to the
downstream responses to titrated KATP channel activity.
One important difference between mouse a and b cells is
that whereas the latter rely exclusively on voltage-gated Ca
2þ
channels for the upstroke of the action potentials, glucagon-
producing a cells are equipped with voltage-gated Na
þ
Figure 10. A Model for the Suppression of Glucagon Secretion by an Intrinsic a-Cell Pathway
Schematic representation of the effects of glucose, tolbutamide, and diazoxide on a-cell KATP,N a
þ, and N-type Ca
2þ (VDCC) channel activities and
glucagon secretion is shown. The insulin response is also shown for comparison with our experimental results (dashed lines, lower panels). The grey
gradient represents a ‘‘window’’ of a-cell KATP channel activity that supports the activation of Ca
2þ and Na
þ channels. Above this window, the cell is
hyperpolarized and Ca
2þ and Na
þ channel activation is prevented, whereas KATP channel activity below this window depolarizes the cell and causes
voltage-dependent inactivation of Ca
2þ and Na
þ channels.
(A) High-glucose concentration reduces a-cell KATP channel activity, reducing glucagon secretion.
(B) Graded application of tolbutamide (in zero glucose) transiently increases glucagon secretion as KATP channel activity is reduced through, and
eventually below, the window supporting glucagon release.
(C) The graded application of diazoxide in high-glucose conditions increases a-cell KATP channel activity into, and then above the window supporting
glucagon secretion. The result is a transient ‘‘re-activation’’ of glucagon secretion at low-diazoxide concentrations.
(D) In low-glucose (1–2 mM) conditions, graded application of diazoxide increases KATP channel activity above the window supporting glucagon
secretion, causing a monotonic inhibition of glucagon release.
doi:10.1371/journal.pbio.0050143.g010
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vation at voltages more positive than  50 mV [14]. This will
reduce the action potential amplitude, and indeed it is
reported that glucose reduces the peak voltage in a cells from
þ11 mV to  1 mV [13]. This will in itself result in an
approximately 35% reduction of exocytosis, which is steeply
dependent on voltage between  10 and þ10 mV (Figure 9E).
The functional signiﬁcance of this is illustrated by the
observations that glucagon secretion and a-cell Ca
2þ re-
sponses at low-glucose concentrations are suppressed by the
Na
þ channel blocker TTX. The exact ion channel comple-
ment of human a cells remains to be established. However,
the fact that glucagon secretion from human islets shows the
same bell-shaped diazoxide concentration dependence as in
mouse islets suggests that the depolarization-induced inacti-
vation of ion channels involved in a-cell regenerative
electrical activity underlies glucose-induced suppression of
glucagon secretion in man as well.
Although L-type VDCCs mediate the majority of Ca
2þ
current in a cells, this work and previous studies [33,44,45]
demonstrate that it is the N-type (x-conotoxin–sensitive)
VDCCs that mediate the Ca
2þ inﬂux necessary for a-cell
exocytosis and glucagon secretion under hypoglycaemic
conditions. We now show that the a-cell N-type VDCCs are
also subject to voltage-dependent inactivation at voltages
more positive than  50 mV and furthermore that this is
associated with reduced exocytotic capacity. It is pertinent
that N-type VDCC-deﬁcient mice exhibit reduced serum
glucagon levels and improved glucose tolerance despite a
parallel reduction in plasma insulin [44]. Although Ca
2þ
inﬂux through L-type Ca
2þ channels does not appear to
contribute much to glucagon secretion under the exper-
imental conditions used in this study, these channels become
the predominant conduit of Ca
2þ entry in the presence of
agents increasing cAMP [41] (unpublished data). The mech-
anism underlying this switch in Ca
2þ channel dependence
remains obscure, but may depend on the strength of
depolarisation because glucagon secretion stimulated by
strong depolarisation with increased K
þ in combination with
KATP channel block can be prevented by inhibition of L-type
Ca
2þ channels [47].
We ﬁnally point out that the model we propose here for the
control of glucagon secretion shares many features with what
is known about the metabolic control of insulin secretion.
This in turn means that processes that interfere with the
ability of, for example, glucose to stimulate insulin secretion
will have the opposite effect on glucagon secretion. This
would provide a simple explanation for the fact that both
insulin and glucagon secretion become perturbed in diabetes
and why oversecretion of glucagon exacerbates the hyper-
glycaemic effects of insufﬁcient insulin secretion.
Materials and Methods
Islet isolation and culture. Islets from female NMRI mice were
isolated by collagenase digestion and cultured in RPMI-1640 media (5
mM glucose) at 37 8C and 5% CO2 for 2 24 h prior to secretion or
intracellular Ca
2þ assays. For single-cell studies, islets were dispersed
in a Ca
2þ-free buffer and plated in 35-mm plastic dishes. Generation
of the Kir6.2Y12X mice, which possess a Tyr12STOP mutation in the
Kcnj11 gene on a BALB/c background, has been described previously
[48]. This results in nonfunctional KATP channels in both a and b cells.
These animals are not overtly diabetic, exhibiting normal fasting
glucose, but are glucose intolerant (R. Cox, unpublished data). For
these experiments, age- and weight-matched wild-type C3HB mice
were used as controls because the Kir6.2Y12X mice were back-crossed
into this background over several generations. Human islets from
four healthy donors were obtained from the Oxford DRWF Human
Islet Isolation Facility. Experiments were performed in duplicate or
triplicate using islets from each donor. Human islets were cultured in
RPMI-1640 (10 mM glucose) at 37 8C and 5% CO2, and experiments
were performed within 48 h of isolation.
Intracellular Ca
2þ measurements. Intact islets were loaded with
ﬂuo-4-AM (1 lM) and fura red (5 lM) in 0.5 mM glucose buffer (see
below) with 0.01% pluronic acid for 30 min at 37 8C. Islets were ﬁxed
with a wide-bore holding pipette within a continuously superfused
and temperature-controlled (37 8C) bath on an Axioskop 2 FS-mot
microscope (Carl Zeiss, http://www.zeiss.com). The perfusion buffer
contained (in mM): 140 NaCl; 3.6 KCl; 2 NaHCO3; 0.5 NaH2PO4; 0.5
MgSO4; 5 HEPES; 2.5 CaCl2; 0.5, 3, or 11 glucose; (pH 7.4 with NaOH).
Laser scanning confocal microscopy was performed using an LSM
510meta system (Zeiss). Excitation was with a 488-nm argon laser, and
emitted ﬂuorescence was collected through 500–550-nm and 650–
710-nm band-pass ﬁlters for the ﬂuo-4 and fura red (FuraR) signals,
respectively. Increases in intracellular Ca
2þ are displayed as upward
deﬂections. Images were acquired at 1.5-s intervals. Individual cells
were selected as regions of interest, and the average ratio intensity (RI
¼[Fluoþ1]/[FuraRþ20]3128þ1) of these were analysed over time with
Origin v7.0220 (OriginLab Corporation, http://www.originlab.com).
Prior to experimental recordings, islets were perfused for 10 min
with the appropriate control solution, and Ca
2þ responses were
monitored periodically during this time to ensure that responses (or
lack thereof) were stable prior to beginning the experimental
recording. Ca
2þ responses were determined by baseline subtraction
and calculation of the integrated response (i.e., the area under the
curve). The slope of this response, reported here as arbitrary units
(AU), was calculated for the ﬁnal 60%–90% of a given treatment
period to allow for equilibration of the responses.
Hormone release. Insulin and glucagon secretion were measured as
described elsewhere [45]. Brieﬂy, batches of ten freshly isolated islets
were pre-incubated in 1 ml of Krebs–Ringer buffer (KRB) supple-
mented with 1 mM glucose for 30 min (rodent) or 1 h (human)
followed by 1-h incubation in 1 ml of test KRB medium supple-
mented as indicated. For experiments in which Zn
2þ was chelated or
GABAA receptors were antagonised (Figure 1), the Ca
2þ-EDTA and
SR-95531, respectively, were present in both the pre-incubation and
test solutions. When extracellular KCl was increased, NaCl was
correspondingly reduced to maintain iso-osmolarity.
Single-cell capacitance and ion current measurements. Whole-cell
currents and exocytosis were recorded using an EPC-9 patch-clamp
ampliﬁer (HEKA Electronics, http://www.heka.com) and Pulse soft-
ware (version 8.50). Single a cells were identiﬁed by their small size
and Na
þ current inactivation properties [58]. This method was
validated by combining the electrophysiological recordings with
subsequent immunostaining for glucagon and insulin. The extrac-
ellular medium contained (in mM): 118 NaCl; 20 TEA-Cl (tetraethy-
lammonium chloride); 5.6 KCl; 2.6 CaCl2; 1.2 MgCl2; 5 HEPES (pH 7.4
with NaOH); and 5 glucose. Except for Figure 8B and 8C, in which the
standard whole-cell conﬁguration was used, the electrophysiological
measurements were conducted using the perforated patch technique,
and the pipette solution contained (in mM): 76 Cs2SO4; 10 NaCl; 10
KCl; 1 MgCl2; and 5 HEPES (pH 7.35 with CsOH). Exocytosis was
monitored as changes in a-cell capacitance using the software-based
lock-in function of the Pulse software. The standard whole-cell
measurements (Figure 8B and 8C) were conducted using a pipette
solution (dialyzing the cell interior) consisted of (in mM) 125 CsOH;
125 glutamate; 10 CsCl; 10 NaCl; 1 MgCl2; 5 HEPES (pH 7.15 with
KOH); 3 Mg-ATP; and 25 lmol/l EGTA (measured resting free Ca
2þ,
;0.2 lmol/l). Pulses were applied at low frequency (,0.05 Hz) to allow
the exocytotic capacity to recover fully between the pulses.
Statistical analysis. Data are presented as means and standard
errors. Signiﬁcance was examined by either the unpaired t-test or by
multiple-comparisons analysis of variance (ANOVA) and post-test, as
appropriate.
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